ALNY Q1 2026 Earnings Call Summary

Alnylam Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Net Product Revenues: Exceeded $1 billion for the first time, reaching $1.036 billion, a 121% increase year-over-year and a 4% increase from Q4 2025.
TTR Franchise Revenue: Generated $910 million, up 153% year-over-year and 6% from Q4 2025.
Rare Disease Revenue: $126 million, a 15% year-over-year increase.
Gross Margin: 80%, down 5% year-over-year due to increased royalties on AMVUTTRA.
Non-GAAP R&D Expenses: $335 million, up 39% year-over-year.
Non-GAAP SG&A Expenses: $283 million, up 36% year-over-year.
Non-GAAP Operating Income: $339 million, over 4x increase compared to last year.
Cash Position: Ended Q1 with $3 billion in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

Continued leadership in TTR amyloidosis with strong commercial execution and new collaborations to enhance disease awareness and patient care.
Progress in R&D with over 25 clinical programs, including the initiation of a Phase I trial for ALN-2232 and positive data presentations for vutrisiran and zilebesiran.
The launch of AMVUTTRA for ATTR-CM has shown strong momentum, with a focus on expanding the prescriber base and enhancing patient access.
Alnylam's strategic vision, "Alnylam 2030," aims to establish global leadership in TTR, innovate sustainably, and scale operations for profitable growth.

3. Forward Guidance and Outlook

Reiterated full-year guidance for TTR product sales between $4.4 billion and $4.7 billion, anticipating significant quarter-over-quarter growth.
Confidence in continued growth driven by AMVUTTRA and a robust pipeline of investigational medicines.
Expected positive contributions from international markets, particularly following the successful launches in Europe and Japan.

4. Bad News, Challenges, or Points of Concern

Collaboration Revenue Decline: Decreased by 17% year-over-year due to a prior milestone payment from Vir in Q1 2025.
Gross Margin Pressure: Expected to decrease further throughout the year due to rising average royalty rates on AMVUTTRA as sales increase.
International Pricing Dynamics: Adjustments in pricing, particularly in Germany, impacted revenues, though anticipated to stabilize and become a net positive over time.
Competitive Landscape: Concerns about potential competition from other silencer therapies and the impact of upcoming clinical data from competitors.

5. Notable Q&A Insights

First-Line vs. Second-Line Use: AMVUTTRA is seeing a balanced initial utilization between first and second lines, with a gradual shift towards increased first-line use as physician experience grows.
Impact of Selling Weeks: Q1 results were affected by fewer shipping weeks, but overall demand growth was strong, with sequential improvements noted throughout the quarter.
Competitive Dynamics: The company remains confident that its growth is not dependent on the timing of generic entries in the stabilizer class, emphasizing the significant unmet need in the TTR space.
Future of Combination Therapies: There is optimism regarding the potential for combination therapies, especially with the upcoming TRITON-CM study for nucresiran, which may provide robust data supporting its use alongside stabilizers.

Overall, Alnylam demonstrated strong financial performance in Q1 2026, with continued confidence in its strategic direction and pipeline, despite facing some challenges related to competition and pricing dynamics.

ALNY — Alnylam Pharmaceuticals, Inc.